766556-56-3

Basic information

• Product Name: Benzoic acid, 4-(3-oxo-4-morpholinyl)-, ethyl ester
• CAS NO: 766556-56-3
• Molecular Formula: C13H15NO4
• Molecular Weight: 249.266
• Mol File: 766556-56-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-(3-oxo-4-morpholinyl)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(3-oxo-4-morpholinyl)-, ethyl ester(766556-56-3)
• EPA Substance Registry System: Benzoic acid, 4-(3-oxo-4-morpholinyl)-, ethyl ester(766556-56-3)

Safety Data

• Hazardous Substances Data: 766556-56-3(Hazardous Substances Data)

Upstream product

• 109-11-5 morpholine-3-one 
• 51934-41-9 4-iodobenzoic acid ethyl ester 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 19614-15-4 4-(morpholin-4-yl)benzoic acid ethyl ester 

Downstream Products

• 820232-33-5 ethyl 4-(3-oxomorpholinyl)cyclohexanecarboxylate 
• 720720-60-5 4-(3-oxomorpholin-4-yl)benzoic acid 

Relevant articles and documents

Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors

Factor Xa (fXa) is a crucial player in various thromboembolic disorders. Inhibition of fXa can provide safe and effective antithrombotic effects. In this study, a series of anthranilamide compounds were designed by utilizing structure-based design strategies. Optimization at P1 and P4 groups led to the discovery of compound 16g: a highly potent, selective fXa inhibitor with pronounced in vitro anticoagulant activity. Moreover, 16g also displayed excellent in vivo antithrombotic activity in the rat venous thrombosis (VT) and arteriovenous shunt (AV-SHUNT) models. The bleeding risk evaluation showed that 16g had a safer profile than that of betrixaban at 1 mg/kg and 5 mg/kg dose. Additionally, 16g also exhibited satisfactory PK profiles. Eventually, 16g was selected to investigate its effect on hypoxia-reoxygenation- induced H9C2 cell viability. MTT results showed that H9C2 cell viability can be remarkably alleviated by 16g.

LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS

The present application describes lactam-containing cyclic diamines and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein M is a non-aromatic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trysin-like serine proteases, specifically factor Xa.